Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial – OncLive
OncLive |
Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial
OncLive Napabucasin is an orally administered small molecule that inhibits the phosphorylation of STAT3, a transcription factor involved in regulating and signaling of embryonic stem cells. Overactivated STAT3 may drive tumor development by helping to maintain … |
